Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1

Blood blood.2023022823.

https://doi.org/10.1182/blood.2023022823

Published: 2024

Includes: Supplemental data

Journal Articles

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Andrzej J Jakubowiak, Sebastien Anguille, Lionel Karlin, Ajai Chari, Carolina Schinke, Leo Rasche, Jesus San-Miguel, Michela Campagna, Brandi W Hilder, Tara J Masterson, Xiang Qin, Thomas Renaud, Jaszianne Tolbert, Deeksha Vishwamitra, Sheri Skerget, Philippe Moreau

Blood (2023) 142 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2023-187242

Published: 2023

Journal Articles

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Tatiana Perova, Onsay Lau, Cuc Davis, Yue Guo, Xin Miao, Tara Stephenson, Caroline Hodin, Clarissa Uhlar, Danielle Trancucci, Katherine Chastain, Nizar J Bahlis, Niels W.C.J. Van De Donk, Raluca Verona

Blood (2023) 142 (Supplement 1): 455.

https://doi.org/10.1182/blood-2023-173550

Published: 2023

Journal Articles

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

Noemie Leblay, Sungwoo Ahn, Sheri Skerget, Rémi Tilmont, Holly Lee, Mansour Poorebrahim, Daniel Penaherrera, Elie Barakat, David Jung, Nizar J Bahlis, Jonathan Keats, Paola Neri

Blood (2023) 142 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2023-189567

Published: 2023

Journal Articles

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Onsay Lau, Cuc Davis, Thomas Renaud, Jaszianne Tolbert, Brandi W Hilder, Tara J Masterson, Michela Campagna, Christoph Heuck, Ajai Chari, Niels WCJ van de Donk, Raluca Verona

Blood (2023) 142 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2023-187755

Published: 2023

Journal Articles

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Blood (2022) 140 (Supplement 1): 241–243.

https://doi.org/10.1182/blood-2022-162709

Published: 2022

Journal Articles

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

Blood (2022) 139 (16): 2471–2482.

https://doi.org/10.1182/blood.2021015161

Published: 2022

Includes: Supplemental data

Journal Articles

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Sheri Skerget, Daniel Penaherrera, Joseph Mikhael, Jonathan J Keats

Blood (2021) 138 (Supplement 1): 726.

https://doi.org/10.1182/blood-2021-148138

Published: 2021

Journal Articles

Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis

Austin Christofferson, BSc, Sheri Skerget, PhD, Jessica Aldrich, Christophe Legendre, PhD, Sara Nasser, PhD, Jennifer Yesil, Daniel Auclair, The MMRF CoMMpass Network, Sagar Lonial, Jonathan J Keats, PhD

Blood (2019) 134 (Supplement_1): 1805.

https://doi.org/10.1182/blood-2019-132152

Published: 2019

Journal Articles

Molecular Characterization of Bone Marrow and Peripheral Blood Compartments from Patients with Plasma Cell Leukemia in the Mmrf Commpass Study

Sheri Skerget, PhD, Austin Christofferson, BSc, Sara Nasser, PhD, Christophe Legendre, PhD, The MMRF CoMMpass Network, Jennifer Yesil, Daniel Auclair, Sagar Lonial, Jonathan J Keats, PhD

Blood (2019) 134 (Supplement_1): 1782.

https://doi.org/10.1182/blood-2019-130697

Published: 2019

Journal Articles

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Benjamin G Barwick, PhD, Sheri Skerget, PhD, Jonathan J Keats, PhD, Daniel Auclair, Sagar Lonial, Lawrence H. Boise, PhD, Paula M Vertino, PhD, Doris R Powell, MA

Blood (2019) 134 (Supplement_1): 858.

https://doi.org/10.1182/blood-2019-124422

Published: 2019

Journal Articles

Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype

Sheri Skerget, PhD, Daniel Penaherrera, BSc, Jessica Aldrich, Sara Nasser, PhD, Austin Christofferson, BSc, Christophe Legendre, Martin Boateng, BS, Lori Cuyugan, Jonathan Adkins, Erica Tassone, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan J Keats, PhD

Blood (2018) 132 (Supplement 1): 111.

https://doi.org/10.1182/blood-2018-99-118617

Published: 2018

Journal Articles

An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma

Sara Nasser, PhD, Jessica Aldrich, Daniel Penaherrera, BSc, Austin Christofferson, BSc, Christophe Legendre, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Sheri Skerget, PhD, Jonathan J Keats, PhD

Blood (2018) 132 (Supplement 1): 113.

https://doi.org/10.1182/blood-2018-99-119354

Published: 2018

Journal Articles

Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis

Daniel Penaherrera, BSc, Sheri Skerget, PhD, Austin Christofferson, BSc, Jessica Aldrich, Sara Nasser, PhD, Christophe Legendre, Martin Boateng, BS, Lori Cuyugan, Jonathan Adkins, Erica Tassone, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan J Keats, PhD

Blood (2018) 132 (Supplement 1): 1895.

https://doi.org/10.1182/blood-2018-99-119610

Published: 2018

Journal Articles

A Molecular Analysis of Cereblon-Related Immunomodulatory Drug Resistance in Commpass Multiple Myeloma Patients

Sheri Skerget, PhD, Brooks Benard, BS, Austin Christofferson, BS, Christophe Legendre, Jessica Aldrich, Sara Nasser, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan J. Keats, PhD

Blood (2017) 130 (Supplement 1): 1754.

https://doi.org/10.1182/blood.V130.Suppl_1.1754.1754

Published: 2017

Journal Articles

CD33 Is Expressed in a Significant Subset of Multiple Myeloma Patients in the US and May Represent a Viable Therapeutic Target

Moshe Levy, MD, Jonathan Keats, PhD, Sheri Skerget, PhD, Dragan Cicic, MD

Blood (2017) 130 (Supplement 1): 5378.

https://doi.org/10.1182/blood.V130.Suppl_1.5378.5378

Published: 2017

Journal Articles

Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An Mmrf Commpass Analysis

Austin Christofferson, BS, Sara Nasser, Jessica Aldrich, Daniel Penaherrera, Christophe Legendre, Brooks Benard, BS, Sheri Skerget, PhD, The MMRF CoMMpass Network, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan Keats, PhD

Blood (2017) 130 (Supplement 1): 326.

https://doi.org/10.1182/blood.V130.Suppl_1.326.326

Published: 2017

NARROW

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis

Molecular Characterization of Bone Marrow and Peripheral Blood Compartments from Patients with Plasma Cell Leukemia in the Mmrf Commpass Study

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype

An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma

Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis

A Molecular Analysis of Cereblon-Related Immunomodulatory Drug Resistance in Commpass Multiple Myeloma Patients

CD33 Is Expressed in a Significant Subset of Multiple Myeloma Patients in the US and May Represent a Viable Therapeutic Target

Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An Mmrf Commpass Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only